Loading
companiesCompany
Recursion Pharmaceuticals
Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.
Overview
Recursion Pharmaceuticals, based in Salt Lake City and listed as RXRX, is an AI-first biotechnology company that merged with Exscientia in 2024, with a clinical oncology pipeline including an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis. Its programmes include REC-1245, the RBM39 degrader in phase 1/2, REC-4881, a MEK1/2 inhibitor in phase 2 for FAP with FDA registrational discussions, and candidates against LSD1, CDK7, PI3K-alpha H1047R, MALT1 and ENPP1, and it reported revenue shortfalls alongside pipeline progress in the first quarter of 2026. OnCo links it to colorectal cancer, AI-driven discovery and protein degradation, the MAPK and cGAS-STING pathways and the idea of a virtual cancer cell. Whether AI-discovered candidates succeed in the clinic at a higher rate than conventional ones is the question the company exists to test.
Similar pages
- CompanyInsilico Medicine
Shares A virtual cancer cell that predicts what a drug will do before you test it, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- IdeaIn silico trials to choose the dose before the first patient
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery, Lab models that fail to predict what happens in patients.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- CompanyIsomorphic Labs
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery, The valley of death between lab and product.
- TechnologyChai-1 / Chai-2
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyESM3 (EvolutionaryScale)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, AI-driven drug & target discovery.
- TechnologyStructural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation).
- InstitutionCancer Center at Illinois
Shares AI-driven drug & target discovery, Lab models that fail to predict what happens in patients, The valley of death between lab and product.